Edwards Lifesciences (EW) VP exercises 11,340 stock options and sells shares

Rhea-AI Filing Summary

Edwards Lifesciences Corp (EW) officer trades company stock through option exercise and sale. On 12/10/2025, the reporting person, a corporate vice president for strategy and corporate development, exercised an employee stock option for 11,340 shares of common stock at an exercise price of $59.2567 per share, then sold the same 11,340 shares at a weighted average price of $83.8255 per share in open-market transactions. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025. After the transactions, the insider directly held 50,356.3707 shares, plus 38,817.6991 shares through a 401(k), 135,152 shares held by a trust, and 45,360 employee stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBO DONALD E JR

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP,Strategy/Corp Development

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		M(1)		11,340	A	$59.2567	61,696.3707	D
Common Stock	12/10/2025		S(1)		11,340	D	$83.8255(2)	50,356.3707	D
Common Stock								38,817.6991	I	401(k)
Common Stock								135,152	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	12/10/2025		M			11,340	06/08/2019	05/07/2026	Common Stock	11,340	$0.0000	45,360	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.

2. This transaction was executed in multiple trades at prices ranging from $83.465 to $84.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edwards Lifesciences (EW) report in this Form 4?

The filing reports that a corporate vice president exercised an employee stock option for 11,340 shares of Edwards Lifesciences common stock at $59.2567 per share and sold those 11,340 shares in the market at a weighted average price of $83.8255 per share on 12/10/2025.

Who is the reporting person in this Edwards Lifesciences (EW) Form 4 and what is their role?

The reporting person is an officer of Edwards Lifesciences with the title CVP, Strategy/Corp Development, indicating a senior executive role overseeing strategy and corporate development.

Was the Edwards Lifesciences (EW) insider trade made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2025.

What prices were involved in the Edwards Lifesciences (EW) insider’s trades?

The employee stock option was exercised at an exercise price of $59.2567 per share, and the resulting 11,340 shares were sold at a weighted average sale price of $83.8255 per share, based on multiple trades between $83.465 and $84.100.

How many Edwards Lifesciences (EW) shares does the insider own after these transactions?

After the reported transactions, the insider directly owned 50,356.3707 Edwards Lifesciences shares, plus 38,817.6991 shares through a 401(k), 135,152 shares held by a trust, and 45,360 employee stock options.

What does the Form 4 say about access to detailed trade prices for the Edwards Lifesciences (EW) sale?

The filing notes that the sale was executed in multiple trades between $83.465 and $84.100, and that the reporting person will provide full details of the number of shares and prices upon request by the SEC staff, the issuer, or a security holder.